Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2017 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results

– Opened two new INDs for wholly-owned SPEAR® T-cell therapies; Company now has four open INDs in 11 indications – – Received orphan designation, PRIME regulatory support and Breakthrough Therapy...
March 08, 2017 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report Fourth Quarter and Full Year 2016 Financial Results on March 13, 2017

PHILADELPHIA and OXFORD, United Kingdom, March 08, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results...
March 02, 2017 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference

PHILADELPHIA and OXFORD, United Kingdom, March 02, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble,...
March 01, 2017 08:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in Philadelphia

PHILADELPHIA and OXFORD, United Kingdom, March 01, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc. (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced it will host a...
February 09, 2017 14:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Participate in Upcoming Investor Conference

PHILADELPHIA and OXFORD, U.K., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe,...
January 09, 2017 08:01 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development

PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Mark E....
January 09, 2017 08:01 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration

PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that...
January 09, 2017 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors

PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the US...
December 19, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc; Bellicum Pharmaceuticals

Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies

PHILADELPHIA and OXFORD, United Kingdom and HOUSTON, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Bellicum...
December 05, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study

PHILADELPHIA and OXFORD, United Kingdom, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...